ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

TPS7585Background: For pts with DLBCL who fail 1st-line therapy, the only potentially curative treatment is salvage chemotherapy followed by autologous stem cell transplant (ASCT). Only »50% of pts...